|
|
Volumn 65, Issue 12, 2005, Pages 1997-
|
|
Mitoxantrone treatment of multiple sclerosis: Safety considerations [8]
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MITOXANTRONE;
ANALGESIC AGENT;
CARDIOTOXICITY;
DRUG EFFICACY;
DRUG MANUFACTURE;
DRUG SAFETY;
HEART FAILURE;
HEART LEFT VENTRICLE EJECTION FRACTION;
HUMAN;
LETTER;
MULTIPLE SCLEROSIS;
PATIENT MONITORING;
PRIORITY JOURNAL;
SCINTIANGIOGRAPHY;
CARDIOMYOPATHY;
CHEMICALLY INDUCED DISORDER;
CONGESTIVE HEART FAILURE;
DOSE RESPONSE;
DRUG EFFECT;
DRUG TOXICITY;
EARLY DIAGNOSIS;
ECHOCARDIOGRAPHY;
ECHOGRAPHY;
GATED IMAGING;
HEART;
MONITORING;
NOTE;
PATHOPHYSIOLOGY;
SCINTISCANNING;
STANDARD;
TREATMENT WITHDRAWAL;
ANALGESICS;
CARDIOMYOPATHIES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG TOXICITY;
EARLY DIAGNOSIS;
ECHOCARDIOGRAPHY;
GATED BLOOD-POOL IMAGING;
HEART;
HEART FAILURE, CONGESTIVE;
HUMANS;
MITOXANTRONE;
MONITORING, PHYSIOLOGIC;
MULTIPLE SCLEROSIS;
WITHHOLDING TREATMENT;
|
|
EID: 33645736061
PISSN: 00283878
EISSN: None
Source Type: Journal
DOI: 10.1212/01.wnl.0000200987.11862.34 Document Type: Letter |
|
Times cited : (7)
|
|
References (0)
|
